Back to Journals » Research and Reports in Urology » Volume 11

Impact of tumor cytoreduction in metastatic prostate cancer

Authors Sow Y, Sow O, Fall B, Sine B, Sarr A, Zé Ondo C, Diao B, Ndoye AK, Ba M

Received 8 February 2019

Accepted for publication 7 April 2019

Published 7 May 2019 Volume 2019:11 Pages 137—142

DOI https://doi.org/10.2147/RRU.S204507

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Dr Jan Colli


Yaya Sow, Ousmane Sow, Boubacar Fall, Babacar Sine, Alioune Sarr, Cyrille Zé Ondo, Babacar Diao, Alain Khassim Ndoye, Mamadou Ba

Urology and Andrology Department at Aristide Le Dantec Hospital, Cheikh Anta Diop University, Dakar, Senegal

Objective: To assess the impact of tumor cytoreduction on cancer outcomes and patient survival in metastatic prostate cancer.
Patients and methods: It is a prospective study spanning a two-year period between October 1st 2015 and March 31st 2017. We enrolled 102 cases of metastatic hormone-sensitive prostate cancer. Fifty-seven (57) patients had exclusively androgen deprivation therapy (ADT) (group 1) and 45 had, in addition, an open prostatectomy or Transurethral resection of the Prostate (group 2). We compared both groups using the total PSA nadir, the time to PSA nadir, the overall survival (OS), and the progression-free survival (PFS).
Results: The average nadir PSA was lower for the tumor cytoreduction group (16.8±1.6 ng/mL (0.01–193.5) versus 110.7±17.9 ng/mL (0.01–1379)). Median time to PSA nadir was shorter in patients in the ADT only group (8 months vs 3 months (p=0.025)). The OS was shorter in patients treated with ADT only compared to the tumor cytoreduction group (median 14 months vs 24 months, respectively (p=0.03)). Similarly, tumor cytoreduction had a positive impact on patient progression (median PFS 20 months (group 1) vs 43 months (group 2)).
Conclusion: Tumor cytoreduction has a positive impact on the oncological results and the survival of patients under ADT.

Keywords: prostate cancer, cytoreduction, androgen suppression, TURP

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]